Following a record-setting spate of settlements, GlaxoSmithKline North America President Dierdre Connelly touts Glaxo’s move away from a sales model that encourages the misbehavior that got the company into trouble, and rejects the argument that fines and settlements are insufficient to change the industry’s behavior. “Our settlement … damaged our reputation and it hurt our morale,” she stated.
MIA relies on the support of its readers to exist. Please consider a donation to help us provide news, essays, podcasts and continuing education courses that explore alternatives to the current paradigm of psychiatric care. Your tax-deductible donation will help build a community devoted to creating such change.